MSFT 447.67 -0.4691% AAPL 208.14 0.3133% NVDA 118.11 -6.684% GOOGL 179.22 -0.2282% GOOG 180.79 0.294% AMZN 185.57 -1.8564% META 498.91 0.8347% AVGO 1592.21 -4.0045% TSLA 182.58 -0.235% TSM 167.81 -3.5353% LLY 890.11 0.7048% V 276.3 0.3924% JPM 198.88 1.3143% UNH 489.98 1.5313% NVO 142.28 0.2254% WMT 68.9 1.4578% LVMUY 155.41 1.3169% XOM 114.04 2.9614% LVMHF 780.0 1.9608% MA 456.96 0.4639%

InMode Ltd

Healthcare US INMD


Last update at 2024-06-24T20:14:00Z

Day Range


52 Week Range



  • Previous Close 18.17
  • Market Cap1660.23M
  • Volume1297881
  • P/E Ratio8.76
  • Dividend Yield-%
  • EBITDA173.36M
  • Revenue TTM466.26M
  • Revenue Per Share TTM5.56
  • Gross Profit TTM 380.79M
  • Diluted EPS TTM2.24


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 201.47M 168.00M 76.13M 62.04M 23.62M
Minority interest 0.00000M -0.10300M 1.51M 3.74M 3.60M
Net income 161.52M 164.97M 75.03M 61.15M 22.37M
Selling general administrative 9.93M 8.41M 6.42M 3.96M 4.81M
Selling and marketing expenses 160.58M 119.35M 86.53M 66.85M 44.62M
Gross profit 380.79M 303.97M 175.26M 136.12M 85.11M
Reconciled depreciation 0.68M 0.52M 0.42M 0.30M 0.18M
Ebit 197.85M 167.48M 72.84M 59.62M 39.49M
Ebitda 198.53M 167.99M 73.26M 59.92M 39.67M
Depreciation and amortization 0.68M 0.52M 0.42M 0.30M 0.18M
Non operating income net other - - - - -
Operating income 197.85M 167.48M 72.84M 59.62M 23.49M
Other operating expenses 256.42M 190.09M 133.27M 96.74M 68.67M
Interest expense 3.61M 0.42M 3.30M 2.41M 0.14M
Tax provision 39.95M 2.93M 1.11M 0.88M 1.26M
Interest income 3.61M 0.53M 3.29M 2.42M 0.14M
Net interest income 3.61M 0.53M 3.29M 2.42M 0.14M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 39.95M 2.93M 1.11M 0.88M 1.26M
Total revenue 454.27M 357.56M 206.11M 156.36M 100.16M
Total operating expenses 182.93M 136.50M 102.42M 76.50M 53.62M
Cost of revenue 73.48M 53.59M 30.85M 20.24M 15.06M
Total other income expense net 3.61M 0.53M 3.29M 2.42M -8.00000M
Discontinued operations - - - - -
Net income from continuing ops 161.52M 165.07M 75.03M 61.16M 22.36M
Net income applicable to common shares 161.52M 164.97M 75.03M 61.02M 21.84M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 863.29M 644.41M 478.54M 295.76M 218.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 15.00M 13.83M 8.40M 1.64M -
Total liab 75.91M 89.79M 62.74M 40.29M 38.58M
Total stockholder equity 787.37M 554.62M 415.80M 255.47M 179.80M
Deferred long term liab - - - - -
Other current liab 36.84M 50.53M 28.06M 16.72M 13.21M
Common stock 0.24M 0.24M 0.24M 0.11M 0.09M
Capital stock 0.24M 0.24M 0.24M 0.11M 0.09M
Retained earnings 693.43M 495.51M 333.99M 169.02M 93.99M
Other liab - 4.26M 7.58M 4.90M 5.34M
Good will - - - - -
Other assets - 7.07M 2.10M 3.44M 2.27M
Cash 144.41M 97.54M 68.14M 68.94M 44.73M
Cash and equivalents - - - - -
Total current liabilities 64.14M 82.02M 51.85M 35.03M 32.49M
Current deferred revenue 10.92M 13.80M 13.80M 11.90M 15.59M
Net debt -135.39400M -92.57800M -64.82900M -68.58000M -43.98300M
Short term debt 2.40M 1.45M 1.21M - -
Short long term debt - - - - -
Short long term debt total 9.02M 4.96M 3.31M 0.36M 0.74M
Other stockholder equity 95.38M 66.36M 82.89M 86.00M 85.60M
Property plant equipment - 7.37M 5.72M 2.13M 2.30M
Total current assets 845.33M 629.37M 470.11M 289.59M 213.21M
Long term investments 0.70M 0.60M 0.60M 0.60M 0.60M
Net tangible assets - 554.62M 415.80M 253.96M 176.07M
Short term investments 597.19M 449.84M 347.78M 191.60M 148.63M
Net receivables 43.63M 42.09M 33.17M 14.07M 10.44M
Long term debt - - - - -
Inventory 45.09M 39.90M 21.03M 14.98M 9.41M
Accounts payable 13.97M 16.24M 8.78M 6.41M 3.70M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.67900M -7.49300M -1.31900M 0.36M 0.12M
Additional paid in capital - - - - -
Common stock total equity - - - 0.11M 0.09M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.67M 3.97M 0.77M 3.37M 0.37M
Deferred long term asset charges - - - - -
Non current assets total 17.96M 15.04M 8.43M 6.17M 5.18M
Capital lease obligations 9.02M 4.96M 4.52M 0.36M 0.74M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -109.47400M -159.16700M -42.84200M -112.45200M -29.73900M
Change to liabilities 8.66M 5.04M -2.80400M 9.76M 5.79M
Total cashflows from investing activities -109.47400M -160.10600M -43.30500M -112.45200M -29.73900M
Net borrowings - - - - -
Total cash from financing activities -41.08500M -15.02200M -12.44200M 70.17M 0.19M
Change to operating activities 16.15M 7.74M 2.18M -7.22200M 9.46M
Net income 161.52M 165.07M 75.03M 61.16M 22.36M
Change in cash 29.40M -0.80200M 24.21M 20.01M 7.13M
Begin period cash flow 68.14M 68.94M 44.73M 24.72M 17.59M
End period cash flow 97.54M 68.14M 68.94M 44.73M 24.72M
Total cash from operating activities 181.58M 174.88M 79.22M 62.21M 36.89M
Issuance of capital stock - 0.00000M 0.00000M 69.78M -
Depreciation 0.68M 0.52M 0.42M 0.30M 0.18M
Other cashflows from investing activities - - - -111.75900M -29.35800M
Dividends paid - - - - -
Change to inventory -18.87100M -6.04300M -5.57500M -2.44500M -1.89100M
Change to account receivables -10.41500M -10.54400M -4.41600M 0.45M -0.57100M
Sale purchase of stock -42.63700M -35.36500M -17.21800M 70.17M 0.19M
Other cashflows from financing activities 1.55M 20.34M 4.78M 0.39M 0.19M
Change to netincome 23.85M 13.21M 14.39M 0.22M 1.54M
Capital expenditures 1.57M 0.94M 0.46M 0.69M 0.38M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.46800M -3.81200M -10.61200M 0.54M 4.79M
Stock based compensation 24.45M 11.96M 12.85M 1.56M 1.95M
Other non cash items -0.69000M 1.91M -0.17800M -0.75400M 8.19M
Free cash flow 180.00M 173.95M 78.76M 61.51M 36.51M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
InMode Ltd
-0.14 0.77% 18.03 8.76 7.25 3.08 1.93 1.59 3.99
Abbott Laboratories
-0.42 0.40% 105.30 37.15 23.15 4.67 4.97 4.88 19.38
Stryker Corporation
-3.57 1.04% 339.07 44.07 24.94 5.51 6.12 6.05 25.73
Medtronic PLC
-0.6 0.73% 81.04 26.60 15.87 3.35 2.08 3.90 14.12
Boston Scientific Corp
-1.0 1.29% 76.71 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News


InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.

InMode Ltd

Tavor Building, Yokne'am, Israel, 2069206

Key Executives

Name Title Year Born
Mr. Yair Malca Chief Financial Officer 1978
Mr. Alon Yaari VP of Operations NA
Ms. Nava Tal-Launer Chief Information Officer NA
Mr. Shakil Lakhani Pres of North America 1983
Dr. Spero Theodorou M.D. Chief Medical Officer 1972
Mr. Moshe Mizrahy Chairman & CEO 1953
Dr. Michael Kreindel CTO & Director 1968
Mr. Shakil Lakhani President of North America 1983
Mr. Alon Yaari Vice President of Operations NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).